Background: Hormone receptor-positive breast cancer is the most common subtype; better tools to identify which patients in this group would derive clear benefit from chemotherapy are needed. Purpose: To evaluate the prognostic potential of diffusion-weighted MRI (DWI) by investigating associations with pathologic biomarkers and a genomic assay for 10-year recurrence risk. Study Type: Retrospective. Subjects: In all, 107 consecutive patients (from 2/2010 to 1/2013) with estrogen receptor (ER)-positive/HER2neu-negative invasive breast cancer who had the 21-gene recurrence score (RS) test (Oncotype DX, Genomic Health). Field Strength/Sequence: Each subject underwent presurgical 3T breast MRI, which included DWI (b 5 0, 800 s/mm 2 ). Assessment: Apparent diffusion coefficient (ADC) and contrast-to-noise ratio (CNR) were measured for each lesion by a fifth year radiology resident. Pathological markers (Nottingham histologic grade, Ki-67, RS) were determined from pathology reports. Medical records were reviewed to assess recurrence-free survival. Statistical Tests: RS was stratified into low (<18), moderate (18-30), and high (>30)-risk groups. Associations of DWI characteristics with pathologic biomarkers were evaluated by binary or ordinal logistic regression, as appropriate, with adjustment for multiple comparisons. Post-hoc comparisons between specific groups were also performed. Results: ADCmean (odds ratio [OR] 5 0.61 per 1 standard deviation [SD] increase, adj. P 5 0.044) and CNR (OR 5 1.76 per 1-SD increase, adj. P 5 0.026) were significantly associated with increasing tumor grade. DWI CNR was also significantly associated with a high (Ki-67 14%) proliferation rate (OR 5 2.55 per 1-SD increase, adj. P 5 0.026). While there were no statistically significant linear associations in ADC (adj. P 5 0.80-0.85) and CNR (adj. P 5 0.56) across all three RS groups by ordinal logistic regression, post-hoc analyses suggested that high RS lesions exhibited lower ADCmean (P 5 0.037) and ADCmax (P 5 0.004) values and higher CNR (P 5 0.008) compared to lesions with a low or moderate RS. Data Conclusion: DWI characteristics correlated with tumor grade, proliferation index, and RS, and may potentially help to identify those with highest recurrence risk and most potential benefit from chemotherapy. Level of Evidence: 3 Technical Efficacy: Stage 3
specific patients in this group who are more likely to recur and/or who would derive clear benefit from chemotherapy is therefore of interest.
Several multigene expression assays for early-stage breast cancer have been developed to provide a more detailed molecular portrait for accurate prognosis. One widely used assay is the 21-gene recurrence score (RS) (Oncotype DX, Genomic Health, Redwood City, CA). RS prognosticates 10-year recurrence risk 3 in hormone receptorpositive, HER2-negative breast cancer. Moreover, RS also predicts likelihood of benefit from adjuvant chemotherapy as measured by an absolute decrease in 10-year distant recurrence rate in both node-negative and -positive patients 4, 5 and predicts the likelihood of pathologic complete response to neoadjuvant treatment. 6 Because of its usefulness in guiding treatment decisions, RS is now incorporated into both American Society of Clinical Oncology (ASCO) 7 and the National Comprehensive Cancer Network (NCCN) 8 treatment guidelines, which specifically recommends the test for hormone receptor-positive, HER2-negative, node-negative tumors, with ongoing larger trials such as SWOG-S1007/RxPonder 9 potentially extending current recommendations to node-positive patients in the near future. In clinical settings, RS significantly influences the recommendation for adjuvant chemotherapy, 10 potentially reducing unnecessary chemotherapy use.
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Despite the described benefits, use of RS is currently limited due to its expense ($4,000). Consequently, there is room for development of alternative markers that may provide prognostic value for less cost or supplemental markers to identify individuals whose care would warrant the RS test. Imaging markers obtained from dynamic contrastenhanced (DCE) magnetic resonance imaging (MRI), which is already often obtained for preoperative evaluation, may address this need. The literature suggests that tumor morphology and kinetic features on DCE-MRI correlate with RS and may be predictive of disease recurrence. [12] [13] [14] [15] [16] In addition to routine DCE-MRI, diffusion-weighted imaging (DWI), a fast and noncontrast-enhanced technique increasingly incorporated into routine breast MRI protocols, may be of supplemental benefit. 17 While DCE-MRI provides information about tumor vascularity, DWI reflects water mobility in tissue, characterizing tumor cellularity. Recent studies have shown DWI measurements to correlate with prognostic markers such as Nottingham grade, 18, 19 Ki-67 score, [20] [21] [22] [23] and expression of HER2, 22, 24 and hormonal receptors 21, 24 in invasive breast cancer. However, few studies specifically evaluate ER-positive cancers, 25 and to our knowledge only one published study to date has specifically investigated DWI as a potential predictor of RS. 26 Thus, the purpose of this study was to confirm associations of DWI characteristics with Nottingham grade and Ki-67 score for the specific subgroup of ER-positive, HER2-negative invasive breast cancers, and to further explore correlations between DWI characteristics and RS.
Materials and Methods
Our study was approved by our Institutional Review Board and was compliant with the Health Insurance Portability and Accountability Act. Requirements for informed consent were waived due to the retrospective nature of the study.
Subjects and Lesions
Our study cohort was obtained by querying our cancer consortium clinical data repository, which compiles data from a variety of sources that include our institutional pathology database, clinical MRI database, and the regional tumor registry. We identified women at least 18 years old who were diagnosed with invasive breast cancer and subsequently underwent both presurgical breast MRI and central RS testing of their tumors from February 1, 2010 to January 31, 2013. For this study, all subjects were required to have undergone the standard breast MRI examination at our institution, which was performed on a 3T scanner and included DWI. From this database inquiry, we identified 111 consecutive women with biopsy-proven hormone receptor-positive, HER2-negative invasive breast cancer meeting study inclusion criteria. Four subjects were excluded from the study: three with obscuration of the breast lesion on MRI due to postbiopsy changes (large hematoma n 5 1, seroma n 5 1, and susceptibility artifact from biopsy clip n 5 1); one for poor lesion visibility on DWI (a small 6 mm nonmass enhancement [NME]), making the ADC measurements unreliable. Thus, the final cohort included 107 women (median age 56, range 32-75 years) with hormone receptor-positive (ER and/or PR), HER2-negative invasive cancer.
Pathologic Assessment
All biopsy specimens pathologically assessed at our institution included verification of invasive cancer, tumor grade (by Nottingham histologic score reflecting tumor cell differentiation based on tubule formation, nuclear grade, and mitotic rate), ER and PR status (by Allred score for expression, where a score 3 is positive), HER2 status (positive or negative by immunohistochemistry and/ or fluorescence in situ hybridization), and Ki-67 proliferation index. Twenty-five tissue samples that were pathologically assessed at outside institutions did not include assessment of Ki-67. A previously proposed prognostic Ki-67 cutpoint of 14% 27, 28 was used to differentiate tumors with low (<14%) and high proliferation rates. RS were stratified into prespecified risk groups of low (<18), moderate (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) , and high (>30), which have been validated in retrospective studies.
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Long-Term Follow-Up
Medical records were reviewed on July 19, 2017 to identify patients who had breast cancer recurrence and determine their length of recurrence-free survival (RFS). Recurrence was defined as any new breast cancer-related diagnosis (local or distant metastasis) after completion of treatment. Recurrence-free survival was defined as the time from definitive (final) surgical treatment to the date of pathologic diagnosis of cancer recurrence or time of last clinical visit in nonrecurring patients. A total of four recurrences were identified.
For each patient who recurred, medical records were reviewed to extract additional associated patient characteristics including genetic mutation, surgical, radiation, and medical treatment received, surgical margins, and site(s) of metastasis. The mean ADC and contrastto-noise ratio (CNR) and RS of tumors that recurred were also noted for comparison with those of the study population.
MRI Acquisition
All patients underwent breast MRI after core biopsy, with a median time between biopsy and MRI of 15 days (range 4-63 days). Breast MR examinations were performed on a Philips Achieva Tx 3T scanner using a dedicated bilateral 16-channel breast coil (MammoTrak, Philips Healthcare, Best, Netherlands). The MRI sequences were acquired in the axial orientation and included T 2 -weighted fast spin echo, T 1 -weighted nonfatsuppressed, T 1 -weighted fat-suppressed DCE-MRI, and DWI. DCE-MRI included one pre-and three postcontrast T 1 -weighted fat-suppressed 3D fast gradient echo (eTHRIVE) sequences, acquired with parallel imaging technique (sensitivity encoding; SENSE). The following imaging parameters were utilized: repetition time / echo time (TR/TE): 5.96/3.09 msec, flip angle: 108, matrix size: 440 3 660, field of view: 22 3 33 cm, number of slices: 280, slice thickness: 1.3 mm, in-plane voxel size: 0.5 mm. The contrast agent administered was 0.1 mmol/kg-body weight gadoteridol (ProHance, Bracco Diagnostics, Princeton, NJ) delivered at 2 cc/s followed by a 20-mL saline flush. DCE-MRI acquisition time was 2 minutes 57 seconds per sequence, with center k-space acquired at 2 minutes; total postcontrast scan time was 8 minutes 51 seconds.
DWI was performed immediately following the DCE-MRI acquisition (typically 9 min postcontrast injection), and was acquired using a diffusion-weighted echo-planar imaging sequence with parallel imaging and fat suppression (spectral attenuated inversion recovery; SPAIR). The following imaging parameters were utilized: TR/TE: 5336/61 msec; reduction factor: 3; averages: 2; matrix size: 240 3 240; field of view: 36 3 36 cm; number of slices: 30; slice thickness: 5 mm; gap: 0. Diffusion gradients were applied in six directions with b values of 0 and 800 s/mm 2 . Acquisition time was 3 minutes 28 seconds.
Image Analysis
DCE-MRI scans were clinically interpreted by one of four fellowship-trained radiologists specializing in breast imaging. Lesion characteristics including lesion type (mass, NME, focus), size, location, and BI-RADS assessment 29 were recorded at the time of interpretation. This information was entered into our clinical database along with detailed histopathology for each lesion and later extracted for the purposes of this study. DWI scans were retrospectively evaluated by a radiology resident (V.N.) under the direct guidance and supervision of a fellowship-trained radiologist (H.R.) specializing in breast imaging with over 5 years of breast MRI experience. DWI was analyzed with custom software developed in Java language and incorporating open source image analysis tools (ImageJ, National Institutes of Health, Bethesda, MD), as previously described. 30 ADC maps were calculated based on a standard monoexponential model: 
where l lesion and l tissue are the mean DWI signal intensities (b 5 800 s/mm 2 ) for lesion and normal tissue ROIs, respectively, and r lesion and r tissue are the corresponding standard deviations. CNR >0 indicates higher signal intensity in the lesion versus normal tissue.
Statistical Analysis
For the primary analysis, associations between lesion DWI measurements (ADCmean, ADCstdev, ADCmax, ADCmin, CNR) and pathologic biomarkers (Nottingham grade; Ki-67; RS risk group) were analyzed using binary and ordinal logistic regression, as appropriate, with P-value adjustment for multiple comparisons using Benjamini and Hochberg's procedure to control the false discovery rate (FDR) at 5%. 34 Additional logistic regression analyses were performed without adjustment for multiple comparisons. These included evaluating associations between lesion morphology on imaging (type: mass vs. NME; maximum diameter) and pathologic biomarkers, post-hoc comparisons of DWI measurements between specific groups, post-hoc multivariate analyses, and pairwise correlation analysis of DWI measurements using Spearman's rank correlation. All DWI measurements were standardized by their mean and standard deviation (SD) so that each logistic regression odds ratio (OR) represents the change per 1-SD increase in the measurement. All analyses were conducted with the statistical computing language R (v. 3.1.1; R Foundation for Statistical Computing, Vienna, Austria). Throughout, two-sided tests were used with statistical significance defined as P < 0.05.
Results
Pathologic characteristics of 107 hormone receptor-positive (ER and/or PR), HER2-negative invasive cancer included in the final assessment are summarized in /s, and CNR ranged from -1.2-6.3 (median 5 2.4). Summary of imaging characteristics stratified by pathologic biomarker subgroups are given in Table 2 . No significant associations of morphologic type and size on MRI with pathologic biomarkers of Nottingham grade, Ki-67 score, and RS were detected (P 5 0.32-0.91 for lesion type and P 5 0.18-0.77 for size).
Correlation of DWI Characteristics With Prognostic Pathologic Factors
In comparison with Nottingham Grade, ADC measures were observed to generally decrease with increasing grade, while CNR measures increased (Fig. 1) . Both tumor ADCmean (OR 5 0.61 per 1-SD increase, p adj 5 0.044) and DWI CNR (OR 5 1.76 per 1-SD increase, p adj 5 0.026) were significantly associated with Nottingham Grade (Table 3) . Similarly, lesions with high Ki-67 proliferation rates (14%) demonstrated higher DWI CNR than lesions with lower proliferation rates (Fig. 2) , which was statistically significant (OR 5 2.55 per 1-SD increase, p adj 5 0.026, Table 3 ).
With respect to RS, the high-risk group was observed to be distinct in terms of ADC and CNR from the lowand moderate-risk groups, which themselves appeared to be similar, rather than DWI metrics steadily increasing or decreasing across RS categories (Fig. 3) . This was confirmed in that the overall linear associations between the DWI parameters and RS (evaluated across the three risk categories) were not significant by ordinal logistic regression (p adj 5 0.56-0.85, Table 3 ), but the high-risk group had significantly lower ADCmean (P 5 0.037) and ADCmax (P 5 0.009) and higher CNR (P 5 0.008) than the combined low and moderate risk group by post-hoc groupwise comparisons (Table 4) . Examples of DCE-MRI, DWI, and ADC images of tumors with low versus high RS are provided in Figs. 4 and 5. Alternatively, there were no significant differences detected in DWI measures when comparing the combined high-and moderate-risk group versus the low-risk group (P 5 0.62-0.92).
Among the DWI metrics that were associated with one or more of the pathological biomarkers, ADCmax and ADCmean were positively correlated (r 5 0.71, P < 0.001) while DWI CNR was not significantly correlated with either ADCmax (r 5 -0.14, P 5 0.15) or ADCmean (r 5 -0.15, P 5 0.13). In a multivariate ordinal logistic regression model, ADCmean (OR 5 0.66 per 1-SD increase, P 5 0.031) and DWI CNR (OR 5 1.65 per 1-SD increase, P 5 0.011) were independently associated with Nottingham Grade. An exploratory multivariate binary logistic regression model of high RS (vs. low and moderate RS) suggested that ADCmax (OR 5 0.14 per 1-SD increase, P 5 0.016) and DWI CNR (OR 5 3.11 per 1-SD increase, P 5 0.020) were each independently associated with high RS, although this assessment is based on only six high-risk lesions.
Recurrence-Free Survival Outcomes
Disease recurrence was detected in four patients over the follow-up period. Of the 103 patients without recurrence, 52 had <5 years of follow-up and 51 had 5 years of follow-up. Of those with disease recurrence, two had low RS and two had moderate RS scores (Table 5) . Two out of four recurrences occurred in patients whose treatment was nonstandard. Recurrent Patient #2 with low RS (RS 5 17) had several unique extenuating circumstances of young age (33 years), BRCA2 mutation, and positive chest wall surgical margins despite several reexcisions after mastectomy. This patient received full treatment with chemotherapy along with aromatase inhibitor, but was diagnosed with with moderate RS (RS 5 27) received chemotherapy in addition to aromatase inhibitor and presented with axillary lymph node metastasis 30 months after surgery. On DWI, although this patient's tumor exhibited a mean ADC score typical of a low/moderate RS, it exhibited a notably high CNR (4.1), which was almost a standard deviation higher than the average CNR of the high RS group. The low number of recurrence events in the study cohort did not allow for statistical analysis.
Discussion
In this retrospective study, we evaluated associations of DWI characteristics of hormone receptor-positive (ER and/ or PR), HER2-negative invasive breast cancers with 21-gene RS recurrence risk and other prognostic factors. We found that ADCmean and DWI CNR correlated with proliferation rate (Ki-67 14%) and Nottingham histologic grade, which agrees with prior studies in invasive breast cancers. Post-hoc analyses suggested that tumor ADC (max and mean) and CNR were also associated with high RS. Our findings suggest that incorporating DWI into breast cancer evaluations may provide additional biological characterization to help in assessing prognosis and guiding clinical management.
The prognostic value of breast tumor MRI characteristics is an emerging area of research. Several studies have recently reported ADC measures to be associated with tumor grade and proliferation. [18] [19] [20] [21] [22] [23] However, these prior DWI studies have not focused specifically on hormone receptor-positive, HER2-negative invasive breast cancers, the most common but heterogeneous group of breast cancers, for which chemotherapy recommendation is variable in practice. Our study validates associations between DWI characteristics and tumor aggressiveness, as measured by Ki-67 and Nottingham histologic grade in this specific cancer subtype.
Furthermore, in post-hoc analysis we found that lesions classified as high risk by RS had lower ADC (mean and max) and higher DWI CNR than low and moderate risk lesions. Only one prior study to date directly explored correlation between DWI and RS in ER-positive, PR-positive, HER2-negative invasive cancers, which demonstrated lower ADC in lesions with higher RS. 26 However, those promising findings were based on a small study population (n 5 31) containing only a single tumor with high RS score. Our study supports an association between ADC and RS in a larger patient cohort and adds to the growing literature showing associations between RS and computer-extracted DCE-MRI lesion characteristics related to size, morphology, kinetics, and texture. [12] [13] [14] [15] [16] In addition to lesion ADCmean values investigated in the prior study, 26 our study evaluated ADCmax, ADCmin, and CNR metrics as well. Biologically, ADC values-particularly ADCmax-would be lowest in homogeneous lesions with high cell density and higher in more heterogeneous or diffuse lesions and/or those with cystic components. On the other hand, minimum ADC values would likely vary less across lesions of varying heterogeneity provided each contains at least some small regions of high cell density. This may explain why ADCmax and ADCmean appeared to be associated with high RS, while ADCmin did not. The standard deviation of ADC values (ADCstdev) also tended to be lower in high RS versus low and moderate RS cancers, which supports this hypothesis of lower microstructural heterogeneity in the high RS cancers. Our observation that DWI CNR was higher in the high-risk group compared to the low-and moderate-risk groups suggests that the higher-risk lesions are more distinct from normal tissue on DWI, likely related to higher relative cellularity and more restricted diffusion. Exploratory multivariate binary logistic regression modeling, although based on a small number of high RS lesions, suggested that DWI CNR and ADCmax were each independently associated with high RS. Following the same trend, multivariate modeling also suggested that ADCmean and DWI CNR were independently associated with Nottingham Grade. Accordingly, our findings suggest ADC and CNR measures may be complementary but independent prognostic factors, warranting further study in larger cohorts.
Long-term follow-up provided some interesting insights, although the low numbers of recurrences in the study cohort precluded any statistical analysis. In the case of one patient with low RS who did not receive chemotherapy and recurred with distant metastases 83 months later, low ADCmean and high CNR might have suggested a more aggressive tumor phenotype, warranting chemotherapy despite a low RS score. Similarly, in another patient with moderate RS who recurred, very high CNR despite moderate ADCmean not only suggests a more aggressive phenotype but also highlights our finding that CNR and ADC may be independent predictive factors. Further investigation to explore the added value of quantitative imaging markers for recurrence prediction modeling may improve outcomes for personalized treatment strategies.
Our study had several limitations. Regarding the MRI technique, we evaluated a limited set of common DWI tumor characteristics. Further study using additional histogram metrics and/or radiomics features to assess lesion morphology and heterogeneity could provide greater insights. As demonstrated by prior DCE-MRI studies, advanced computerized image feature extraction techniques to measure a wider range of textural characteristics may demonstrate additional prognostic value. The slice thickness of our DWI acquisition was 5 mm in order to achieve an adequate signal-to-noise ratio, which could result in partial volume averaging. Higher spatial resolution techniques hold the potential to improve the ability to characterize DWI features of breast lesions, in particular for small and nonmass-type lesions. 36 Lesions were evaluated on MRI after core needle biopsy, and the presence of postbiopsy changes may have affected the MRI measurements, although care was taken to exclude obvious hematomas and seromas for quantitative measurements. All DWI examinations were performed after DCE-MRI and it is possible that signal intensity on DWI could be affected by residual gadolinium, although we have previously shown no significant effect on breast tumor ADC measures using our imaging protocol. 30 Regarding our study population, although we incorporated all three risk groups of RS, a larger proportion of patients were in the low-and moderate-risk groups compared to the high-risk group. The previous study by Thakur et al 26 also had a similar limitation, which is presumably due to selection bias of patients who undergo genomic testing, based on clinical decisions between physicians and patients (ie, clinicians may more likely order testing in patients they feel to be of unclear risk and are undecided whether benefits from chemotherapy treatment outweigh the risk). Our study also included 20 patients with nodepositive disease. Although more recent studies have suggested both prognostic and predictive benefit of the Oncotype Dx 21-gene RS in node-positive cancers, 5,37 current NCCN guidelines only recommend the use of RS in nodenegative, ER-positive cancers. 8 In our analysis, "low,"
"moderate," and "high" RS scores were defined in accordance with original cutoffs published by Paik et al. 3, 4 More recent studies have used a lower RS (<11) to define low recurrence risk 38, 39 ; this new definition has been adopted in the upcoming 2018 American Joint Committee on Cancer (AJCC) 8 th edition staging guidelines. 40 Lastly, while the associations of DWI parameters with Nottingham Grade and Ki-67 were statistically significant after accounting for the number of comparisons in the primary analysis, the associations of the DWI parameters with high RS were detected during a subsequent post-hoc analysis and require further validation in a larger study population.
In conclusion, we found associations between DWI characteristics and multiple prognostic factors including RS, suggesting that these imaging biomarkers may reflect recurrence risk and likelihood of benefit from chemotherapy. More specifically, our findings suggest that DWI measures of ADCmean, ADCmax, and CNR may help discriminate higher-risk lesions with more aggressive biology within the most common and diverse subgroup of hormone receptorpositive/HER2-negative breast cancers. This is clinically relevant given that patients with a high RS have been shown retrospectively to benefit the most from adjuvant chemotherapy treatment, while the lower-risk groups have minimal benefit. 4 These results suggest that DWI may provide helpful prognostic information for newly diagnosed breast cancers, and support the inclusion of DWI in preoperative MRI examinations used to evaluate extent of disease. In limited resource settings where costly genetic testing cannot be performed on all patients with hormone receptor-positive breast cancer (the most common subtype), DWI, along with DCE-MRI, may serve as a potential alternative or a triaging tool in identifying the subset of high-risk patients who would benefit from the genetic test. Further investigation of MRI and DWI biomarkers is warranted to determine the associations with long-term clinical outcomes and to incorporate MRI characteristics into current predictive risk models for personalized breast cancer treatment.
